NOT FDA-APPROVED

Pinealon

A small Russian-developed tripeptide for cognitive function, from the same St. Petersburg research tradition that produced Epithalon, Selank, and Semax. Aimed at the brain side of aging.

The 30-second read

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology, the same Vladimir Khavinson research tradition that produced Epithalon, Selank, and Semax. It's aimed at neuroprotection and age-related cognitive decline rather than telomeres or anxiety. Russian preclinical and clinical research has reported neuroprotective effects in models of stroke, hypoxia, and oxidative damage, plus cognitive improvements in elderly subjects. Like the rest of the Russian-tradition peptides, it's not FDA-approved and Western replication is limited. Used in nootropic and longevity-research circles, especially alongside Epithalon for a "telomere + neuroprotection" pairing.

Why this peptide is on people's radar

Pinealon comes from the same long Russian peptide-research program as Epithalon, Selank, and Semax. Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson program operates on a specific theory: that short peptides extracted (and later synthesized) from particular organs can modulate the function of those organs in ways that connect tissue physiology to overall aging biology. Pinealon was identified in that framework as a peptide aimed at the brain side of aging.

Russian preclinical research has reported neuroprotective effects in models of stroke, hypoxic injury, oxidative damage, and excitotoxicity. Russian clinical work has reported cognitive improvements in elderly subjects with mild cognitive impairment. The findings are encouraging within the Khavinson research program, but as with Epithalon and Selank, the same caveats apply: the work is concentrated in one institute, Western replication has not happened at scale, and the methodological standards differ from modern FDA-style clinical trials.

In nootropic and longevity-research communities outside Russia, Pinealon shows up most often as a brain-axis complement to Epithalon's telomere/longevity emphasis. The pairing makes intuitive sense (Khavinson's framework treats them as part of the same aging-modulation toolkit), even though the human evidence for either combination or individual use has the same source-bias issues.

What people are usually trying to do with it

People exploring Pinealon are usually focused on:

Cognitive support through age-related decline
Neuroprotection, preserving brain function against oxidative and ischemic stress
Recovery from concussion or post-stroke cognitive symptoms
Pairing with Epithalon for a longevity-plus-cognition protocol
An alternative to Semax for cognitive support, with a different mechanism

What the science actually shows

Plain-English summary:

Neuroprotection in animal models

Russian preclinical research reports protection against neuronal damage in models of hypoxia, ischemia, and oxidative stress.1

Cognitive improvement in elderly populations

Russian clinical studies in elderly patients with mild cognitive impairment have reported improved memory and attention scores. Studies are smaller and less rigorously blinded by Western RCT standards.2

Mechanism, gene expression and oxidative defense

Mechanistic work suggests Pinealon influences gene expression patterns associated with neuronal survival and antioxidant defense.3

What hasn't been demonstrated

FDA approval. Independent Western replication of the Russian clinical findings. Long-term safety with continuous use. Direct comparisons against Western standard-of-care for cognitive disorders.

The honest read

What's solid:

The Khavinson research program is real and decades-long. The mechanistic story for short peptides modulating tissue-specific gene expression is biologically plausible. Pinealon's preclinical neuroprotection story is reasonably consistent within the published Russian literature.

What's still unproven:

The same source-bias issue that affects every Russian-tradition peptide on this site. Most of the published research comes from one institute. Independent replication outside Russia is limited. Long-term safety in healthy adults using Pinealon for cognitive support has not been rigorously characterized.

What's hyped beyond the evidence:

"Brain rejuvenation" framings. The clinical evidence is in elderly populations with measurable cognitive impairment, not healthy adults seeking enhancement. Marketing that conflates the two overstates what the evidence supports.

Things to know if you're looking into it

How it's used in research: typically a small subcutaneous injection or intranasal spray, often given in cycles (10-20 day courses repeated 1-2x per year) reflecting Russian protocol patterns.
Often paired with Epithalon: the Khavinson framework treats them as complementary. Epithalon for telomere/longevity, Pinealon for cognition.
Regulatory status: not FDA-approved. Approved in Russia under a national framework. Not on the FDA Category 2 list as of 2026.
Reported tolerability: generally favorable in published research and community use. Mild and uncommon side effects.
Healthcare provider involvement: recommended, especially for anyone with cognitive concerns serious enough to warrant proper neurological evaluation first.
Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

How is Pinealon related to Epithalon?

Same research tradition, different molecules. Both came from Vladimir Khavinson's St. Petersburg Institute. Epithalon is a tetrapeptide aimed at telomere biology; Pinealon is a tripeptide aimed at neuroprotection and cognition. They're often paired in longevity protocols within the Khavinson framework.

Is it FDA-approved?

No. Not approved by the FDA. Approved in Russia under their national regulatory framework, which doesn't translate to FDA approval.

Will it improve my memory?

Russian clinical data in elderly populations with mild cognitive impairment is encouraging. Whether it produces meaningful effects in healthy adults seeking cognitive enhancement hasn't been rigorously studied.

How does it differ from Semax?

Both are Russian-tradition cognitive peptides, but different molecules and slightly different positioning. Semax is an ACTH(4-7) analog focused on neuroplasticity and stroke recovery. Pinealon is a tripeptide with a neuroprotection / oxidative-defense emphasis.

Are there side effects?

Reported side effects in Russian clinical literature and community use are uncommon and mostly mild. Long-term safety in healthy adults using continuous protocols is not characterized.

Why is most research from one institute?

Pinealon emerged from the Khavinson research program at the St. Petersburg Institute of Bioregulation and Gerontology, which has built a coherent body of work on short bioregulator peptides over decades. That concentration is both a strength (consistent methodology, deep institutional expertise) and a limitation (independent replication outside that group is limited).

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Approved in Russia under their regulatory framework. Not currently on the FDA Category 2 list. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, side-effect profile, and references.

Background

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, as part of the broader Khavinson research program on short bioregulator peptides. The program has identified and synthesized peptides aimed at modulating the function of various organ systems, pineal (Epithalon), thymic (Thymalin), CNS (Pinealon, Semax-related work), under the theoretical framework that short peptides regulate tissue-specific gene expression in ways relevant to aging.

Mechanism of action

Neuroprotection and oxidative defense

Animal studies report that Pinealon protects neurons against hypoxic and oxidative damage, with proposed mechanisms involving modulation of antioxidant gene expression and direct effects on neuronal survival pathways.

Gene expression effects

Like Epithalon, Pinealon is theorized within the Khavinson framework to bind regulatory regions of DNA and modulate expression of genes involved in neuronal function, oxidative defense, and cellular senescence.

Half-life

Plasma half-life is short, minutes, consistent with cycle-based dosing rather than continuous daily use.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Subcutaneous (research range): 5 to 10 mg per dose, given once daily for 10 to 20 days, repeated 1 to 2 times per year. Cycle-based pattern reflecting Russian protocol design.

Intranasal alternative: some research-community protocols use intranasal administration, similar in pattern to Selank/Semax.

Side effects and safety profile

Mild injection-site reactions (uncommon)
Mild fatigue or initial sleep disturbance (uncommon)
Generally favorable tolerability in published research and community use

Long-term safety in healthy adults using continuous protocols is not characterized.

References

Khavinson VK, Lin'kova NS, Kvetnoy IM, et al. (2012). "Tetrapeptide AEDG (Epitalon) regulates pineal gland function and Tripeptide EDR (Pinealon) regulates brain function." Bull Exp Biol Med, 153(6), 870–873. PubMed
Khavinson VK, Diomede F, Mironova E, et al. (2020). "AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism." Molecules, 25(3), 609. PubMed
Lin'kova NS, Polyakova VO, Trofimov AV, et al. (2014). "Tissue-specific peptides (Pinealon, Vesugen) and human gene expression in the brain." Bull Exp Biol Med, 156(6), 822–824. PubMed

For educational and research purposes only. This is not medical advice. Pinealon is not FDA-approved. Most published clinical evidence comes from one Russian research institute; Western replication is limited. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.